Literature DB >> 28326838

CTLA-4 gene polymorphisms associate with efficacy of postoperative radioiodine-131 for differentiated thyroid carcinoma.

De-Feng Chang1, Xiao-Hong Chen1, Jing Huang2, Ya-Mei Sun1, Da-Yong Zhu1, Zhong-Qing Xu1.   

Abstract

AIM: To investigate the association of CTLA-4 polymorphisms with efficacy of postoperative radioiodine-131 (I-131) treatment for differentiated thyroid carcinoma (DTC).
METHODS: A total of 324 DTC patients and 350 healthy individuals were enrolled in our study. Patients received I-131 remnant ablation following surgical resection. Based on the treatment efficacy, patients were divided into the effective (n = 183) and ineffective groups (n = 141). CTLA-4 polymorphisms (+49A>G, CT60A>G and -318C>T) were genotyped by polymerase chain reaction-restriction fragment length polymorphism.
RESULTS: AG + AA genotype distribution and A allele frequency of +49A>G and CT60A>G polymorphisms were higher in the effective group than the ineffective group.
CONCLUSION: +49A>G and CT60A>G polymorphisms were associated with the efficacy of postoperative I-131 treatment for DTC; and they might be bioindicators related to the prognosis of I-131 treatment.

Entities:  

Keywords:  +49A>G; -318C>T; CT60A>G; CTLA-4 gene; differentiated thyroid carcinoma; efficacy; polymorphism; radioiodine-131

Mesh：

Substances：

Year:  2017        PMID： 28326838     DOI： 10.2217/fon-2016-0399

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  2 in total

1.  Comprehensive Analysis of 29,464 Cancer Cases and 35,858 Controls to Investigate the Effect of the Cytotoxic T-Lymphocyte Antigen 4 Gene rs231775 A/G Polymorphism on Cancer Risk.

Authors:  Hongyuan Wan; Hangsheng Zhou; Yanyan Feng; Yongquan Chen; Lijie Zhu; Yuanyuan Mi
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Association between CTLA-4 + 49A > G and - 318C > T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm.

Authors:  Shabnam Abtahi; Fatemeh Izadi Jahromi; Mohammad Hossein Dabbaghmanesh; Mahyar Malekzadeh; Abbas Ghaderi
Journal:  Endocrine       Date:  2018-08-04       Impact factor: 3.633
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.